Search Results - "Skintemo, L."

ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer by Carlsson, G.U., Guren, T.K., Haux, J., Pfeiffer, P., Taflin, H., Mavroudis, D., Georgoulias, V., Papadimitriou, C., Kentepozidis, N., Boumpas, D., Skintemo, L., Ganlöv, K.M.E., Gustavsson, B.

Get full text

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer by Carlsson, G., Koumarianou, A., Guren, T.K., Haux, J., Katsaounis, P., Kentepozidis, N., Pfeiffer, P., Brændengen, M., Mavroudis, D., Taflin, H., Skintemo, L., Tell, R., Papadimitriou, C.

“…5-fluorouracil (5-FU) combined with a folate remains an essential treatment component for metastatic colorectal cancer (mCRC). Leucovorin is the folate most…”
Get full text

569PISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer by Carlsson, G U, Guren, T K, Haux, J, Pfeiffer, P, Taflin, H, Mavroudis, D, Georgoulias, V, Papadimitriou, C, Kentepozidis, N, Boumpas, D, Skintemo, L, Ganlöv, K M E, Gustavsson, B

Get full text